Symbol="IVVD"
AssetType="Common Stock"
Name="Invivyd Inc."
Description="Adagio Therapeutics, Inc., a clinical-stage biopharmaceutical company, is focused on the discovery, development and commercialization of antibody-based solutions for infectious diseases in the United States. The company is headquartered in Waltham, Massachusetts."
CIK="1832038"
Exchange="NASDAQ"
Currency="USD"
Country="USA"
Sector="LIFE SCIENCES"
Industry="BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)"
Address="303 WYMAN STREET, SUITE 300, WALTHAM, MA, US"
FiscalYearEnd="December"
LatestQuarter="2023-06-30"
MarketCapitalization="184390000"
EBITDA="-165468000"
PERatio="None"
PEGRatio="None"
BookValue="2.57"
DividendPerShare="0"
DividendYield="0"
EPS="-1.72"
RevenuePerShareTTM="0"
ProfitMargin="0"
OperatingMarginTTM="0"
ReturnOnAssetsTTM="-0.259"
ReturnOnEquityTTM="-0.503"
RevenueTTM="0"
GrossProfitTTM="0"
DilutedEPSTTM="-1.72"
QuarterlyEarningsGrowthYOY="0"
QuarterlyRevenueGrowthYOY="0"
AnalystTargetPrice="2.5"
TrailingPE="-"
ForwardPE="-"
PriceToSalesRatioTTM="-"
PriceToBookRatio="0.499"
EVToRevenue="-"
EVToEBITDA="0.821"
Beta="-0.0474"
num_52WeekHigh="4.89"
num_52WeekLow="0.98"
num_50DayMovingAverage="1.357"
num_200DayMovingAverage="1.714"
SharesOutstanding="109756000"
DividendDate="None"
ExDividendDate="None"
symbol="IVVD"
open="1.58"
high="1.71"
low="1.58"
price="1.68"
volume="172464.00"
latest_trading_day="2023-08-21"
previous_close="1.57"
change="0.11"
change_percent="7.0064%"
aroon_positive_momentum_days="0"
aroon_negative_momentum_days="87"
trend_strength="Absent or Weak Trend"
buying_signal="Weak Sell Signal"
volume_analysis="Target Volume"
value_analysis="Expected Range"
Aroon_change="FALSE"
Aroon_momentum="13"
Volume_recent_avg="326563"
Change_recent_avg="0.01"
Delta_recent_avg="0.13"
Variance_recent_avg="0.07"
Change_ratio_recent_avg="-0.28"
RSI_change="FALSE"
ADX_change="FALSE"

event="FALSE"
Aroon_signal="negative"
Aroon_change="FALSE"
Aroon_momentum_positive="13"
Aroon_momentum_negative="87"
image_negative_thumbnail_id_1="1089"
image_negative_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Negative_Landscape_0122.jpeg"
image_negative_thumbnail_id_2="146"
image_negative_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/05/MI_Finance_Negative_Landscape_0030.jpeg"
image_neutral_thumbnail_id_1="595"
image_neutral_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Neutral_Landscape_0004.jpeg"
image_neutral_thumbnail_id_2="578"
image_neutral_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Neutral_Landscape_0021.jpeg"
image_positive_thumbnail_id_1="984"
image_positive_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Positive_Landscape_0146.jpeg"
image_positive_thumbnail_id_2="651"
image_positive_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Positive_Landscape_0057.jpeg"
image_professor_thumbnail_id_1="1189"
image_professor_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Professor_Landscape_0023.jpeg"
image_professor_thumbnail_id_2="1199"
image_professor_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Professor_Landscape_0033.jpeg"
